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the post-aprotinin era. Circulation. 2011;124(11 Suppl):S62-9.TARYFacts, opinions, and conclusions: Aprotinin brings out all of theseVictor A. Ferraris, MD, PhDIn general, an opinion is a subjective belief, and is the result
of emotion or interpretation of facts. An opinion may besupported by an argument, although people draw opposing
opinions from the same set of facts. Almost all cardiac sur-
geons have an opinion about the use of aprotinin. These
opinions range from strong support for drug use to adamant
insistence that the drug causes harm. The facts that the sup-
porters and detractors use to form their opinions are the
same. Only conclusions differ.
WHATARE THE FACTS?
Fact 1: Aprotinin Reduces Bleeding, Blood
Transfusion, and Reoperation for Bleeding in
Patients Having a Variety of Cardiac Operations
There can be little doubt of this fact. In developing prac-
tice guidelines about blood conservation for the Society ofery c January 2013
P
M
Ferraris CommentaryThoracic Surgeons, we identified>500 published articles
that addressed the use of aprotinin for limiting bleeding
and blood transfusion after cardiac operations.1 This vol-
ume of literature represented the most studied facet of blood
conservation by a huge margin. In fact, the next closest
blood conservation intervention had<50 citations in the lit-
erature. Later on, it was even criticized that too many redun-
dant trials addressed efficacy questions already answered
definitively by previous studies.2 Given the volume of
published literature, it is not surprising that multiple
meta-analyses exist to address the efficacy of aprotinin in
reducing bleeding end points. The manuscript by Howell
and coworkers3 is another example of one such meta-
analysis that shows the benefit of aprotinin in limiting reop-
eration resulting from bleeding. If cardiac surgeons believe
in randomized trials and published observational data, they
should believe that aprotinin reduces bleeding and blood
transfusion.
Fact 2: The Means of Controlling or Evaluating the
Safety and Clinical Efficacy of a Drug After Its
Regulatory Approval Are Ineffective
It is clear from the aprotinin story that randomized, con-
trolled studies, which are the prerequisite for regulatory ap-
proval, do not reflect necessarily the real world of medical
practice. More important, rare or uncommon complications
are often lost in the relatively uniform populations found in
randomized trials. Large clinical databases are valuable ad-
juncts to the discovery of adverse events related to drug or
device therapy. For example, it seems apparent that a rela-
tionship exists between aprotinin and perioperative renal
dysfunction. Whether this means that aprotinin causes this
renal dysfunction or is simply associated with this compli-
cation remains debatable. Furnary and coauthors4 examined
their large database to investigate the effect of aprotinin on
renal function. They found significant association between
postoperative renal dysfunction and blood transfusion, but
not with use of aprotinin.4 Others found opposite results af-
ter examining large databases.5
Because of safety concerns about aprotinin, the Canadian
Institutes of Health Research and the Ontario Ministry of
Health sponsored a randomized trial comparing aprotinin
with tranexamic acid in high-risk cardiac operations (the
BloodConservationUsingAntifibrinolytics inaRandomized
[BART] trial).6 Early discontinuation of the BART trial be-
cause of supposed excessmortality in the aprotinin group sig-
naled the death knell of aprotinin in the United States. Since
publication of this study, Health Canada reexamined the
BART trial data and concluded ‘‘that the benefits of Trasylol
outweigh the risks when Trasylol is used as authorized by
Health Canada. Trasylol is authorized for patients undergo-
ing coronary artery bypass graft (CABG) surgery. The evi-
dence does not suggest an increased risk of death in this
use. As a result of this assessment, the manufacturer, BayerThe Journal of Thoracic and CaInc, can resume the marketing of Trasylol in Canada.’’2 For
various reasons, possibly related to medical malpractice liti-
gation, Bayer Pharmaceuticals, the manufacturer of aproti-
nin (Trasylol) will not reintroduce aprotinin into the U.S.
market (personal communication, Bayer representative,
June 2012). This drug is now available in Canada and other
countries.
The European Medicines Agency is a European Union
agency for the evaluation of medicinal products. Roughly
parallel to the U.S. Food and Drug Administration, but
without Food and Drug Administration–style centraliza-
tion, the European Medicines Agency recommended tem-
porary withdrawal of Trasylol in 2007 after publication of
the BART trial suggested increased risk of complications
or death. Ultimately, Bayer suspended Trasylol sales in
May 2008. In February 2012, the European Medicines
Agency scientific committee reversed its previous stand-
point regarding aprotinin, and recommended that the sus-
pension be lifted and that aprotinin be used as previously
indicated. The shifting back and forth of the regulatory bod-
ies as they approve or disapprove use of aprotinin highlights
the ineffective postapproval surveillance that exists both in
the United States and abroad.
WHATARE THE OPINIONS?
Opinion 1: Lysine Analogs Are Not Safer Than
Aprotinin
Because of the widespread use of aprotinin in cardiac op-
erations, large clinical databases discovered a relationship
between aprotinin and certain adverse outcomes. The safety
of aprotinin data was called into question. Examination of
theMulticenter Study of Perioperative Ischemia Epidemiol-
ogy II database conveyed early concerns about renal toxicity
and mortality risk associated with aprotinin.5 These safety
concerns caused authors to recommend lysine analogs (tra-
nexamic acid and epsilon amino caproic acid) as a safer sub-
stitute for aprotinin.7 Much less safety data exist for the
lysine analogs compared with the vast clinical experience
reported for aprotinin. With the absence of aprotinin in the
cardiac armamentarium, both tranexamic acid and epsilon-
aminocaproic acid use increased. With this increase in use
of other antifibrinolytic agents, some safety concerns arose.
For example, most regulatory agencies in Europe have not
approved Amicar for use in cardiac operations because of
concerns about thrombosis. Seizure risk seems to be in-
creased with use of high-dose tranexamic acid.8 It may be
that wider use of lysine analogs will uncover safety issues
not recognized in randomized trials. There is insufficient ev-
idence to suggest that lysine analogs are safer than aprotinin.
Opinion 2: Perioperative Blood Transfusion Causes
Death or Serious Morbidity
In most, but not all, studies that evaluate complications
associated with aprotinin use, there is no difference inrdiovascular Surgery c Volume 145, Number 1 241
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treated with aprotinin and those treated with either placebo
or other antifibrinolytic agents. This finding is reinforced in
the manuscript by Howell and coworkers,3 who found no
difference in mortality between aprotinin-treated patients
and either placebo-treated patients or lysine analog-
treated patients. This observation leads some surgeons to
question whether postoperative bleeding is an important
outcome. The fact that aprotinin decreases bleeding but
does not alter significantly operative mortality or serious
morbidity diminishes the importance of bleeding in some
surgeons’ eyes. By logical extension, some surgeons sug-
gest that blood transfusion does not cause serious morbidity
or death, but is simply associated with these outcomes.
Sicker patients are likely to have worse outcomes and are
more likely to require blood transfusion than less sick pa-
tients. This association may occur because of prolonged op-
erations in older patients who are more likely to be anemic
and to have more comorbidities. Transfusion is likely in
these high-risk patients, but the transfusion itself may not
cause adverse outcomes; it is simply associated with
them. Advocates of the cause/effect relationship between
blood transfusion and adverse outcomes cite evidence
from randomized trials like those tested in an intensive
care unit setting.9 Others admit that there is no really strong
evidence to support this relationship, and suggest that a re-
strictive transfusion strategy needs to be tested in large clin-
ical trials.10 I suspect there will never be a truly randomized
trial to test the cause-and-effect relationship between blood
transfusion and adverse nonbleeding surgical outcomes.
Surgeons are not willing to assign transfusion or no transfu-
sion randomly in high-risk patient groups. We are left with
observational studies and large database studies to form an
opinion about the cause-and-effect relationship between
blood transfusion and adverse outcomes. There is increas-
ing evidence that blood transfusion is the culprit—not the
innocent bystander—in all types of operative proce-
dures.11-15 Opinions vary about this subject, but I bet that
blood transfusion is an active contributor to serious
morbidity and operative mortality in patients having
cardiac operations.
WHATARE THE CONCLUSIONS?
Aprotinin reduces perioperative blood loss, blood trans-
fusion, and reexploration for bleeding in cardiac operations.
Experiencewith this drug is extensive andmost of the safety
concerns have been uncovered. The same cannot be said for
lysine analogs. The aprotinin story points out the need for242 The Journal of Thoracic and Cardiovascular Surgdrug surveillance following regulatory approval. Reforms
are badly needed in this area.
Blood transfusion and perioperative bleeding are likely
offenders in development of serious postoperative compli-
cations and operative mortality. Synthesis of facts and opin-
ions points to the need to minimize blood transfusion to
improve surgical outcomes. Too bad aprotinin is not here
to help U.S. surgeons with this problem.References
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